NCT00837759TERMINATEDanonymous

Novel Therapy Combining Regenerative Stimuli Immunomodulation to Preserve Beta Cell Function in New Onset Type 1 Diabetes

Sponsor

Source record

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Phase

Source record

Phase 2

Modality

AI-normalized

small molecule

Target

AI-normalized

Beta cell function in Type 1 Diabetes

Indication / condition

AI-normalized

Diabetes Mellitus Type 1

Intervention

Source record

Insulin, Lansoprazole, Sitagliptin, Diamyd, GAD65 (Diamyd)

Related intelligence directories

Indication directory: Diabetes Mellitus Type 1 Modality directory: small molecule Target directory: Beta cell function in Type 1 Diabetes

Source & freshness

Source record

NCT ID

NCT00837759

Original source

ClinicalTrials.gov

Source last updated

Jan 03, 2013

Ingested at

May 23, 2026

Internal sync

Jun 05, 2026

Model version

trialsignal-ai-v1

Normalized confidence

88%

Validation status

validated

Open original registry record

View original source fields

NCT ID

NCT00837759

Title

Novel Therapy Combining Regenerative Stimuli Immunomodulation to Preserve Beta Cell Function in New Onset Type 1 Diabetes

Sponsor

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Status

TERMINATED

Phase

Phase 2

Condition raw

Diabetes Mellitus Type 1

Condition normalized

Diabetes Mellitus Type 1

Modality raw

Diabetes Mellitus Type 1

Modality normalized

small molecule

Target raw

Beta cell function in Type 1 Diabetes

Target normalized

Beta cell function in Type 1 Diabetes

Interventions

Insulin, Lansoprazole, Sitagliptin, Diamyd, GAD65 (Diamyd)

Public preview

Source record

This clinical trial aimed to evaluate a combination therapy of sitagliptin, lansoprazole, and Diamyd to preserve beta cell function in newly diagnosed Type 1 Diabetes (T1D) patients. The study was terminated due to changes in study personnel before full subject accrual.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Early access offer

Subscribe with code FOUNDERS5 for a 5-day premium trial.

Full protocol, outcomes, eligibility, contacts and results sections

Patent/IP landscape with verified records when available

Board-ready PDF export with source provenance

Save to folders and synthesize multiple assets in premium workspace

Create account

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

Novel Therapy Combining Regenerative Stimuli Immunomodulation to Preserve Beta Cell Function in New Onset Type 1 Diabetes

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 20, 2026

NCT ID

NCT00837759

Status

TERMINATED

Phase

Phase 2

Sponsor

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Executive brief

Investment-Ready Snapshot

Source & freshness

Provenance

SourceClinicalTrials.gov

Source updatedJan 03, 2013

Internal syncJun 05, 2026

Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT00837759

Indication

Diabetes Mellitus Type 1

Modality

small molecule

Target

Beta cell function in Type 1 Diabetes

Intervention

Insulin, Lansoprazole, Sitagliptin, Diamyd, GAD65 (Diamyd)

Source record